This morning’s pick, Modern Mobility Aids, (OTCBB: MDRM) could start climbing up the charts today based on recent news!

MDRM just announced that it is buying a 100 Percent stake in “LumiGene,” a company that developed a diagnostic device that could become a standard in hospitals and clinics worldwide!

LumiGene’s Diagnostic breakthrough technology could change the entire pharmaceutical industry as it seeks to become the point of source diagnostic device favored by most hospitals around the world!

The trends in medicine are changing. The current worldwide focus on reducing medical care costs while maintaining quality of care has encouraged the movement of in vitro testing out of the central laboratories and into the patient care setting.

In recent years, diagnostic tests that can be performed nearer to the point of care (POC) have emerged as an important tool in disease diagnosis and management, and are increasing in popularity due to their clinical benefit and cost-effectiveness.

That is why we believe LumiGene’s breakthrough technology is so amazing and MDRM is an amazing opportunity Right Now!

LumiGene’s POSiChek™ Diagnostic System is a nucleic acid (DNA or RNA) testing system that automates the process of preparing and amplifying nucleic acid in order to detect disease causing pathogens (i.e. bacteria or viruses) all within 30-60 minutes.

Because of this technology, within minutes, decisions can be made and actions taken which could result in:

Faster & better treatments
Decreased pain & suffering
Reduced economic costs
Increased public safety
Saved lives

We encourage our subscribers to research this company immediately and do not miss this opportunity to potentially gain profits! Visit MDRM Group today!

The time to act on MDRM is now before the rest of the street realizes its tremendous potential!